Search results
Showing 1576 to 1590 of 8900 results
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Evidence-based recommendations on vutrisiran (Amvuttra) for wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for treating active non-radiographic axial spondyloarthritis.
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Tofacitinib for treating active ankylosing spondylitis (TA920)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.
Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Upadacitinib for treating active ankylosing spondylitis (TA829)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.